ConSynance Therapeutics Announces U.S. FDA Grants Rare Pediatric Disease Designation to CSTI-500, a Potential First-in-Class Therapy for Prader-Willi Syndrome FDA awards ConSynance's CSTI-500 Rare Pediatric Disease Designation for innovative Prader-Willi Syndrome treatment.

Rocket delivers cell samples to ISS to study effects of microgravity on muscles ORLANDO, Fla., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Several Central Floridians are on a mission in space — well, a small part of them, anyway. Muscle cells from research study participants at...

Sage UK Implements Harte-Hanks Trillium Software(R) Data Quality Solution ALDERMASTON, UNITED KINGDOM--(Marketwire - August 9, 2007) - Harte-Hanks Trillium Software (NYSE: HHS), a leading enabler of Total Data Quality solutions, today announced Sage (UK) Limited as a new...